Introduction
Technology valuation is a critical component in licence agreements, influencing negotiation strategies and deal structures. Various methods exist to assess the value of technology, each suited to different stages of development, market conditions, and risk profiles. This practice note provides an overview of the main valuation approaches, practical examples, and insights to help licensors and licensees make informed decisions.
Methods of Technology Valuation in Licensing
| Method | Principle | Best Use Case | Example |
| Cost-Based | Technology is valued based on the cost to develop or replace it. | Early-stage technologies with uncertain market potential. | A university-developed catalyst cost R10M in R&D. The licence fee is set to recover part of that cost, e.g., R2M upfront plus milestone payments. |
| Market-Based | Value is benchmarked against comparable deals, industry royalty rates, or similar transactions. | Sectors with transparent benchmarks (pharma, software, consumer electronics). | A mobile app API licence is priced at 5% of net sales, based on comparable SaaS licensing deals in the industry. |
| Income-Based (DCF) | Value is the present value of expected future cash flows (royalties, profits). | Mature technologies with predictable commercialization pathways. | A licensed technology is expected to generate R6M per year for 5 years → Total expected sales: R30M At a 5% royalty, expected income is R1,5M. After a simple risk adjustment (80%), the indicative value is: R1,2M Key idea: The technology is valued based on the income it is expected to earn, adjusted for realistic risk. |
| Option-Based (Real Options) | Technology is treated as a financial option, valuing flexibility to expand, delay, or abandon commercialization. | High-risk, innovative technologies with uncertain adoption (AI, biotech). | A biotech firm licenses a gene-editing tool with staged payments: R1M upfront, plus R5M if clinical trials succeed — reflecting the “option” to continue. |
| Hybrid/Negotiated | Combines elements of cost, market, and income approaches, adjusted by bargaining power and strategic fit. | Complex, multi-party deals (engineering + IP + supply contracts). | A hybrid plant construction licence: upfront fee based on R&D cost, royalties tied to production output, and milestone payments linked to regulatory approvals. |
Principles in Practice
- Cost-Based → Anchors value in sunk costs. Simple, but ignores market demand.
- Market-Based → Relies on comparables. Strong when data is available, but often confidential.
- Income-Based (DCF) → Forward-looking, captures commercial potential. Sensitive to assumptions.
- Option-Based → Captures uncertainty and strategic flexibility. Complex but powerful for emerging technology.
- Hybrid → Pragmatic, reflects negotiation realities. Often the most realistic in cross-border or multi-technology deals.
Negotiation Insight
In practice, valuation is less about finding “the true number” and more about framing negotiation anchors.
- Licensors often prefer income-based (to capture upside).
- Licensees often argue cost-based (to limit exposure).
- Market comparables are used as sanity checks.
- Hybrid structures (upfront + royalties + milestones) balance risk and reward.
The hybrid approach is particularly relevant. It allows parties to design modular frameworks where:
- Upfront fees cover sunk R&D costs,
- Royalties reflect market comparables,
- Milestones hedge uncertainty (option-based logic),
- Performance guarantees tie into engineering/supply contracts.
The key is to find the right valuation method depending on technology maturity, market data availability, and negotiation leverage.
Conclusion
Technology valuation in licensing is a nuanced process that requires balancing multiple methods to reflect the unique characteristics of each deal. By understanding the principles and best use cases of cost-based, market-based, income-based, option-based, and hybrid approaches, licensors and licensees can better negotiate terms that align with their strategic and financial goals.
Disclaimer
This practice note is intended for informational purposes only and does not constitute legal or financial advice. Readers should consult with qualified professionals before making licensing or valuation decisions.
[Note: Practice note updated on 18 March 2026.]